News

The round was led by OrbiMed and included participation from Fidelity Management & Research Company, Rock Springs Capital, Quan Capital and Nest Bio. This financing brings the total

The new Phase 2b proof-of-concept study, called Imbokodo, aims to enroll 2,600 HIV-negative women in sub-Saharan Africa. Of 1.8 million new HIV infections worldwide in 2016, 43 percent

Sublocade’s approval is for patients who had started treatment with a transmucosal buprenorphine-containing product and have been on a stable dose of the treatment for at least seven

Based on the Phase 2 safety and efficacy results, along with guidance from the FDA and EMA, Revance plans to proceed to a Phase 3 program in cervical

This includes three marketed products: recently approved and launched Vabomere (vaborbactam/meropenem), and established commercial products Orbactiv (oritavancin) and Minocin IV (minocycline).  The acquisition was unanimously approved by Melinta’s

Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study, dubbed Strive.  Erenumab functions by targeting and inhibiting the Calcitonin Gene-Related Peptide

The trial showed statistically significant and dose dependent increases in lean body mass and less head following treatment with VK5211 compared against placebo. In addition, the study also reached secondary endpoints,

Titan and Molteni, a European-based pharmaceutical company focused on treatments for pain and drug addiction, expect to enter into the definitive license and distribution agreement during the first

The randomized, placebo-controlled, double-blind phase 1 trial will feature 240 male and female subjects aged between 18 and 49. It will assess the safety and immunogenicity of the investigational